The Readout Loud
by STAT
Latest episode
421: The future of heart drug research in the wake of study setbacks
421: The future of heart drug research in the wake of study setbacks
About this podcast
STAT’s weekly biotech podcast, breaking down the latest news, digging deep into industry goings-on, and giving you a preview of the week to come.
Episodes
The newest 50 of 426 episodes
- 421: The future of heart drug research in the wake of study setbacks · 20 minOn this week’s episode of "The Readout LOUD": the failure of two closely followed heart disease drugs and how these setbacks may impact the future of cardiovascular drug…
- 420: Democrats’ midterm victory, and a questionable fertility procedure · 30 minHow will the midterm results affect drug pricing policy? What is the fate of the Food and Drug Administration? And why are women traveling to fertility clinics abroad? On this…
- 419: Assessing Merck and Moderna's mRNA cancer vaccine · 20 minWhat is Adam doing in Spain? How did doctors react to detailed data on Merck and Moderna's mRNA cancer vaccine? And what are the next big advances in oncology? On this week's…
- 418: Remembering STAT’s Helen Branswell · 35 minHelen Branswell was a renowned infectious disease reporter who earned the respect and admiration of experts and public health officials with her authoritative, prescient…
- 417: Hospitals' next lucrative bet — longevity clinics · 20 minLongevity medicine is now estimated to be a multitrillion dollar industry. But what are people paying for, and does it work? On this week's episode of “The Readout LOUD,” STAT's…
- 416: NIH funding uncertainty thwarts U.S. researchers · 34 minHow has the National Institutes of Health been spending its budget? Why are biotech investors feeling gloomy? And what is the most quintessential Boston movie? We discuss all…
- 415: Mistrust in science and a juicy gene-editing lawsuit · 31 minOn this week’s episode of "The Readout LOUD": Why have so many Americans lost trust in science? And how have our policy leaders fueled that mistrust? We speak to STAT’s new…
- The FDA's Overton era, and dispatches from Shanghai · 30 min"The Readout LOUD" is going international this week. STAT's Jason Mast joins the podcast from Shanghai, where he's digging into what the rise of Chinese drug development means…
- Definium's new psychedelics data, and a reprieve for international scientists · 28 minInternational researchers got a reprieve in the courts this week. But many are still considering leaving the states for opportunities elsewhere. What does that mean for the…
- Why two promising heart drugs flopped and what's next · 31 minOn this week’s episode of “The Readout LOUD”: The pharma industry invested billions of dollars to develop drugs heralded as the next era in the treatment of heart disease — but…
- 411: Capricor's data clash and a fugitive in the C-suite · 37 minIs the Food and Drug Administration taking inconsistent approaches to Duchenne muscular dystrophy drugs? How will a new batch of drug executives shake up their companies? And why…
- 410: A father’s mission to save his daughter, and allegations on telehealth GLP-1 prescribing · 1 h 4 minWhat does it take to develop a therapy for an ultra-rare disease? What are the allegations against a telehealth company that’s partnered with Novo Nordisk? And has a wanted…
- 409: Predicting biotech clinical trials & a new Alzheimer's drug controversy · 36 minOn this week’s episode of "The Readout LOUD": The Kalshi prediction markets are coming for biotech, plus the controversy over an experimental Alzheimer’s disease treatment from…
- 408: Whistleblower takes on health insurance and FDA commissioner candidates · 44 minWhy does getting family health insurance through a job cost as much as buying a new car? How did a whistleblower take on an insurance contractor? And who might be the new Food…
- 407: The mysterious case of Eli Lilly's obesity drug · 43 minWho got exclusive access to Eli Lilly's highly anticipated obesity candidate? Why are drugmakers spending so much money on acquisitions? And are hair loss drugs a good…
- 406: New hope in treating Huntington's disease and a report card on RFK Jr.'s promises · 36 minThis week: New hope for people living with Huntington’s disease, and a report card on RFK Jr.’s effort to remake health in America. The Food and Drug Administration reversed its…
- 405: An obesity drug deep-dive, and peptides move mainstream · 36 minCan any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow…
- 404: What RevMed's pancreatic cancer drug meant for one patient · 38 minWhy did oncologists give a standing ovation to a data presentation on Revolution Medicines' pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this…
- 403: Biotech exec Jeremy Levin on the industry's strategic turning point · 47 minOn this week’s episode of “The Readout LOUD,” we chat with longtime biotech executive Jeremy Levin about his new book, “Biotech in the Balance: Saving a Strategic Industry in an…
- 402: Guarding biotech from China and big bets in longevity · 44 minOn this week’s episode of “The Readout LOUD,” the hosts discuss STAT's Breakthrough Summit West, where powerful leaders from health care and science rubbed shoulders. They share…
- 401: Makary’s departure and Cassidy’s tenuous Senate seat · 41 minThis week’s episode of “The Readout LOUD” is all about health politics. We bring on FDA reporter Lizzy Lawrence to discuss Makary’s departure — why he is leaving, which of his…
- 400: Seaport's IPO adventure, obesity pill battles, and Makary's troubles · 33 minOn this week’s episode of "The Readout LOUD," we chat with Seaport Therapeutics CEO Daphne Zohar, fresh off the biotech’s successful IPO. Plus, Elaine, Allison, and Adam chat…
- 399: Hair-raising trial results, and Servier’s M&A wishlist · 41 minWhy are investors excited about hair loss drugs? Will artificial intelligence make clinical trials run more smoothly? And how does a nonprofit pharma company compete in the M&A…
- 398: A CAR-T biotech's dramatic turnaround, and drugmakers' tactics to drive more scripts · 38 minHow did a biotech company that almost ran out of money three times get acquired for over $3 billion? Will the M&A streak continue? And why are drugmakers working with a…
- 397: A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment · 50 minOn this week’s episode of the Readout LOUD: a pancreatic cancer breakthrough and new hope for an off-the-shelf CAR-T treatment in lymphoma. Your favorite biotech podcasting crew…
- 396: A new trick for old science, and biotech VCs' scrambled playbook · 32 minWhy is old exon science getting new traction? What’s unsettling biotech VCs? And who will be the next CEO of PhRMA? Adam is out, so Elaine and Allison dive into the latest news…
- 395: Biotech investors' plea to Trump, and a busy M&A week · 32 minHow has the Food and Drug Administration's recent decisions on rare disease drugs affected investment trends? Why is Eli Lilly getting into sleep medicine? And where did Allison…
- 394: Eli Lilly's deal man, Allogene's off-the-shelf CAR-T, and Merck's Terns buy · 26 minOn this week’s episode of "The Readout LOUD": Allison DeAngelis is still away, leaving Elaine Chen and Adam Feuerstein to mind the podcasting store. You've been warned. Eli…
- 393: A conversation with the 'godfather' of biotech · 45 minOn this week's episode of "The Readout LOUD," we bring you a special conversation with Stelios Papadapolous, also know as the "godfather" of biotech. He sat down for an on-stage…
- 392: Epstein's pal attempts a biotech comeback, and Prasad exits the FDA · 31 minHow was a known friend of Jeffrey Epstein able to raise $100 million, with the help of a prominent biotech VC? And will Vinay Prasad return to the Food and Drug Administration…
- 391: Breaching the IBD efficacy ceiling, and sham surgeries · 30 minWill drugmakers finally be able to breach the efficacy ceiling in inflammatory bowel disease? And is the Food and Drug Administration being flexible enough with rare disease…
- 390: FDA turmoil, election intrigue, AI, and more · 33 minOn "The Readout LOUD" this week: Adam Feuerstein, solo. His usual co-hosts Allison DeAngelis and Elaine Chen took some time off, so Adam manned the podcast mic himself. Adam…
- 389: Hims' Super Bowl fallout, and the FDA reverses course · 34 minWas Hims' Super Bowl ad the final straw for regulators? Is the bar being lowered for psychedelic medicines? And what's happening behind-the-scenes with Moderna and the Food and…
- 388: The FDA's refusal to review Moderna's mRNA flu vaccine · 51 minWe’re devoting our entire episode this week to one controversial and impactful topic: the FDA’s decision to block the review of Moderna’s mRNA flu shot. STAT was the first to…
- 387: Challenges for a crucial sickle cell treatment and the latest outlook for GLP-1s · 28 minOn this week’s episode of The Readout LOUD: two starkly different financial outlooks from Novo Nordisk and Eli Lilly, a psychedelics drug from Compass Pathways encountered a…
- From Drug Story: Lipitor and Heart Disease · 1 h 1 minThis is an episode of Drug Story, a podcast by Thomas Goetz. You can find the rest of the series at https://www.drugstory.co/podcast Once you turn 40, it seems like half the…
- 386: The high stakes for Huntington's patients · 42 minBiotech company UniQure is set to meet with the Food and Drug Administration to discuss the path forward for its gene therapy for Huntington's disease, and the outcome could be…
- 385: A measles outbreak and hospitals' financial troubles · 30 minWhy is the U.S. at risk of losing its measles elimination status? How are health officials reacting to the measles outbreak? And what did top Centers for Medicare and Medicaid…
- 384: Live from the JP Morgan conference, a sit-down with Novo Nordisk's CEO and VC Bob Nelsen · 1 h 8 minFor this very special episode of The Readout LOUD Allison, Adam, and Elaine are live from the J.P. Morgan Healthcare Conference in San Francisco. The hosts are joined by ARCH…
- 383: JPM to bring more deals and happy CEOs · 34 minWhat news happened over the holidays? Why will pharma CEOs be greeted warmly in San Francisco next week? And who will buy Revolution Medicines? We discuss all that and more on…
- 382: Biotech's year in review · 34 minIs the biotech industry truly out of its slump? Why are employers dropping coverage of weight loss drugs? And what will the hosts bake for the holidays? We discuss all that and…
- 381: The future of American science and a dispatch from ASH · 33 minHow did Terns Pharmaceuticals and its “hodgepodge” pipeline grab attention at the American Society of Hematology conference? Is Eli Lilly’s new drug making people lose too much…
- 380: A new top drug regulator and the future of psychedelics · 33 minOn this week’s episode of "The Readout Loud": a look at an emerging class of psychedelic drugs that may treat depression, anxiety, and other psychiatric conditions without the…
- 379: How Mark Cuban plans to ‘f— up’ health care · 37 minHow much time does Mark Cuban spend thinking about health care? Why does he think TrumpRx, a direct drug purchasing platform that the Trump administration aims to launch, is “the…
- 378: Merck's heart disease win and the FDA's new drug regulator · 36 minWhat does Rick Pazdur's new role mean for the Food and Drug Administration? Has Merck solved the PCSK9 access issue? And how much credit can the president take for lowering GLP-1…
- 377: Melodrama at the FDA and the Pfizer-Novo bidding war · 31 minOn a jam-packed show, your co-hosts, minus the vacationing Allison DeAngelis, chat with STAT’s D.C. correspondent Lizzy Lawrence about a slow-boiling feud between Vinay Prasad…
- 376: BridgeBio’s great week and Moderna’s unraveling · 38 minHas BridgeBio’s business model worked? How are executives at Moderna dealing with the company’s slump? And who will the hosts dress up as for Halloween? We discuss all that on…
- 375: Startups push the FDA and biotech booms in North Carolina · 29 minCan Trump take credit for North Carolina's booming biopharma industry? Which drugs could get a shortcut to the market? And who wore a tuxedo to the STAT Summit? We discuss all…
- 374: Veteran biotech executive Clive Meanwell on drug pricing and the obesity market · 34 minOn this week’s episode of “The Readout LOUD”: an interview with veteran biotech executive and company founder Clive Meanwell. Pfizer recently acquired one of Meanwell’s…
- 373: Party in biotech land and AstraZeneca’s miscalculation · 46 minWhere did former vaccine regulator Peter Marks find a new job? How did a math error cost AstraZeneca a rare disease candidate? And is biotech back? We discuss all that on this…








